SIRT1(rs7069102 ) Gene Polymorphism in Chronic Obstructive Pulmonary Disease at Egyptian Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic obstructive pulmonary disease (COPD) prevalence, morbidity, and mortality vary across countries and across different groups within countries with a direct relation to the prevalence of tobacco smoking. Other risk factors for COPD include genetic factors, longstanding asthma, outdoor air pollution, second-hand smoke exposure, biomass smoke, indoor air pollution, occupational exposures, and tuberculosis . The prevalence and burden of COPD are projected to increase in the coming decades because of continued exposure to COPD risk factors and the changing age structure of the world's population. As these factors are rapidly increasing in developing countries, COPD will become a major health problem, exerting a huge demand on economic and healthcare resources in developing countries \[2\]. In Egypt, although COPD is a rising significant health problem, data on its prevalence, morbidity, and mortality are still lacking and have to be estimated .

Sirtuin 1 (SIRT1) is a protein/histone deacetylase dependent NAD. It plays a crucial role in various human diseases such as cardiovascular diseases, cancer, inflammation, aging, neurodegenerative disease, obesity and type 2 diabetes. Seven isoforms of the SIRT1 gene (SIRT1- SIRT7) have been determined in mammals. Expression of the SIRT1 gene is regulated by transcription factors such as CREB, FOXO3, HIC1, NF-KB, p53, PARP-2 and PPAR. SIRT1

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COPD Prognosis in Covid Patients

NCT05274490

Respiratory Failure

COMPLETED

Self-management Program in Patients With COPD

NCT07068269

Chronic Obstr Lung Disease

RECRUITING NA

Respiratory Muscle Strength in Patients With Idiopathic Pulmonary Fibrosis

NCT03588260

Idiopathic Pulmonary Fibrosis

COMPLETED

Digital Health Integration With Pulmonary Rehabilitation on Patients With Chronic Obstructive Lung Disease

NCT06582082

Chronic Obstructive Lung Disease

RECRUITING NA

Pulmonary Rehabilitation in Functional Outcomes and Its Relationship With Morbidity and Mortality in Patients With COPD

NCT03692793

Pulmonary Disease, Chronic Obstructive

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genotyping of SIRT1in Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients more than 40 years

genotyping of SIRT1 in chronic obstructive patients

Intervention Type GENETIC

genotyping of SIRT1 in chronic obstructive patients

patients less than 40 years

genotyping of SIRT1 in chronic obstructive patients

Intervention Type GENETIC

genotyping of SIRT1 in chronic obstructive patients

controls

genotyping of SIRT1 in chronic obstructive patients

Intervention Type GENETIC

genotyping of SIRT1 in chronic obstructive patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

genotyping of SIRT1 in chronic obstructive patients

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients admitted to Sohag University Hospital, chest department.

Exclusion Criteria

* Patients with malignancies, any other chronic disease, Individuals with a history of known chronic cardiorespiratory diseases and those with collagen vascular diseases were excluded.

Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No